Zacks: Analysts Anticipate AxoGen, Inc (NASDAQ:AXGN) Will Post Earnings of -$0.10 Per Share

Brokerages expect AxoGen, Inc (NASDAQ:AXGN) to announce ($0.10) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for AxoGen’s earnings, with estimates ranging from ($0.13) to ($0.08). AxoGen posted earnings of ($0.05) per share in the same quarter last year, which would suggest a negative year over year growth rate of 100%. The firm is scheduled to announce its next earnings results on Monday, November 4th.

According to Zacks, analysts expect that AxoGen will report full year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.52) to ($0.40). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.26) per share, with EPS estimates ranging from ($0.44) to ($0.14). Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for AxoGen.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. AxoGen had a negative return on equity of 16.73% and a negative net margin of 26.91%. The business had revenue of $26.70 million during the quarter, compared to analysts’ expectations of $26.77 million. During the same period in the previous year, the firm earned ($0.09) earnings per share. The firm’s quarterly revenue was up 29.7% compared to the same quarter last year.



A number of brokerages recently commented on AXGN. ValuEngine raised AxoGen from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Canaccord Genuity set a $30.00 price objective on AxoGen and gave the stock a “buy” rating in a research note on Wednesday, August 7th. JMP Securities decreased their price objective on AxoGen from $43.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Cantor Fitzgerald decreased their price objective on AxoGen from $30.00 to $21.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Finally, William Blair cut AxoGen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $31.00.

Shares of AxoGen stock traded up $0.27 during trading on Friday, reaching $11.85. 163,398 shares of the company were exchanged, compared to its average volume of 392,941. The company has a quick ratio of 7.87, a current ratio of 8.70 and a debt-to-equity ratio of 0.02. AxoGen has a twelve month low of $10.91 and a twelve month high of $39.33. The business has a 50-day moving average price of $14.27 and a 200-day moving average price of $18.65. The firm has a market capitalization of $455.36 million, a price-to-earnings ratio of -21.94 and a beta of 0.17.

In other AxoGen news, insider Isabelle Billet bought 5,635 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was purchased at an average cost of $15.11 per share, with a total value of $85,144.85. Following the completion of the purchase, the insider now owns 4,630 shares in the company, valued at $69,959.30. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CIO Daniel Pietrzak bought 10,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was acquired at an average cost of $5.65 per share, with a total value of $56,500.00. Over the last three months, insiders acquired 107,535 shares of company stock valued at $1,389,672. Insiders own 6.77% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Advisor Group Inc. boosted its position in shares of AxoGen by 86.3% during the second quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 1,180 shares during the period. Stonebridge Capital Advisors LLC acquired a new position in shares of AxoGen during the second quarter worth about $59,000. Aperio Group LLC acquired a new position in shares of AxoGen during the second quarter worth about $77,000. Quantamental Technologies LLC boosted its position in shares of AxoGen by 188.5% during the second quarter. Quantamental Technologies LLC now owns 4,128 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 2,697 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of AxoGen by 82.6% during the second quarter. Bank of Montreal Can now owns 6,595 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 2,984 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Story: Balance Sheet

Get a free copy of the Zacks research report on AxoGen (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.